The global non-alcoholic fatty liver disease (NAFLD) drug market size is calculated at USD 21.98 billion in 2025 and is forecasted to reach around USD 33.6 billion by 2034, accelerating at a CAGR of 4.83% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Revenue and Volume Forecast, by Drug Class
8.1.1. Antioxidants
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Lipid-Lowering Agents
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Thiazolidinedione
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. FXR Receptor Agonists
8.1.4.1. Market Revenue and Volume Forecast
8.1.5. Fibrosis Treatment Agents
8.1.5.1. Market Revenue and Volume Forecast
8.1.6. Biguanides
8.1.6.1. Market Revenue and Volume Forecast
8.1.7. Other Drug Classes
8.1.7.1. Market Revenue and Volume Forecast
9.1. Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Revenue and Volume Forecast, by Stage
9.1.1. Cirrhosis
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Fibrosis
9.1.2.1. Market Revenue and Volume Forecast
10.1. Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Revenue and Volume Forecast, by Distribution Channel
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Drug Stores
10.1.2.1. Market Revenue and Volume Forecast
11.1. Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market Revenue and Volume Forecast, by Disease Cause
11.1.1. Obesity
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Heart Disease
11.1.2.1. Market Revenue and Volume Forecast
12.1. North America
12.1.1. Market Revenue and Volume Forecast, by Drug Class
12.1.2. Market Revenue and Volume Forecast, by Stage
12.1.3. Market Revenue and Volume Forecast, by Distribution Channel
12.1.4. Market Revenue and Volume Forecast, by Disease Cause
12.1.5. U.S.
12.1.5.1. Market Revenue and Volume Forecast, by Drug Class
12.1.5.2. Market Revenue and Volume Forecast, by Stage
12.1.5.3. Market Revenue and Volume Forecast, by Distribution Channel
12.1.5.4. Market Revenue and Volume Forecast, by Disease Cause
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Volume Forecast, by Drug Class
12.1.6.2. Market Revenue and Volume Forecast, by Stage
12.1.6.3. Market Revenue and Volume Forecast, by Distribution Channel
12.1.6.4. Market Revenue and Volume Forecast, by Disease Cause
12.2. Europe
12.2.1. Market Revenue and Volume Forecast, by Drug Class
12.2.2. Market Revenue and Volume Forecast, by Stage
12.2.3. Market Revenue and Volume Forecast, by Distribution Channel
12.2.4. Market Revenue and Volume Forecast, by Disease Cause
12.2.5. UK
12.2.5.1. Market Revenue and Volume Forecast, by Drug Class
12.2.5.2. Market Revenue and Volume Forecast, by Stage
12.2.5.3. Market Revenue and Volume Forecast, by Distribution Channel
12.2.5.4. Market Revenue and Volume Forecast, by Disease Cause
12.2.6. Germany
12.2.6.1. Market Revenue and Volume Forecast, by Drug Class
12.2.6.2. Market Revenue and Volume Forecast, by Stage
12.2.6.3. Market Revenue and Volume Forecast, by Distribution Channel
12.2.6.4. Market Revenue and Volume Forecast, by Disease Cause
12.2.7. France
12.2.7.1. Market Revenue and Volume Forecast, by Drug Class
12.2.7.2. Market Revenue and Volume Forecast, by Stage
12.2.7.3. Market Revenue and Volume Forecast, by Distribution Channel
12.2.7.4. Market Revenue and Volume Forecast, by Disease Cause
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Volume Forecast, by Drug Class
12.2.8.2. Market Revenue and Volume Forecast, by Stage
12.2.8.3. Market Revenue and Volume Forecast, by Distribution Channel
12.2.8.4. Market Revenue and Volume Forecast, by Disease Cause
12.3. APAC
12.3.1. Market Revenue and Volume Forecast, by Drug Class
12.3.2. Market Revenue and Volume Forecast, by Stage
12.3.3. Market Revenue and Volume Forecast, by Distribution Channel
12.3.4. Market Revenue and Volume Forecast, by Disease Cause
12.3.5. India
12.3.5.1. Market Revenue and Volume Forecast, by Drug Class
12.3.5.2. Market Revenue and Volume Forecast, by Stage
12.3.5.3. Market Revenue and Volume Forecast, by Distribution Channel
12.3.5.4. Market Revenue and Volume Forecast, by Disease Cause
12.3.6. China
12.3.6.1. Market Revenue and Volume Forecast, by Drug Class
12.3.6.2. Market Revenue and Volume Forecast, by Stage
12.3.6.3. Market Revenue and Volume Forecast, by Distribution Channel
12.3.6.4. Market Revenue and Volume Forecast, by Disease Cause
12.3.7. Japan
12.3.7.1. Market Revenue and Volume Forecast, by Drug Class
12.3.7.2. Market Revenue and Volume Forecast, by Stage
12.3.7.3. Market Revenue and Volume Forecast, by Distribution Channel
12.3.7.4. Market Revenue and Volume Forecast, by Disease Cause
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Volume Forecast, by Drug Class
12.3.8.2. Market Revenue and Volume Forecast, by Stage
12.3.8.3. Market Revenue and Volume Forecast, by Distribution Channel
12.3.8.4. Market Revenue and Volume Forecast, by Disease Cause
12.4. MEA
12.4.1. Market Revenue and Volume Forecast, by Drug Class
12.4.2. Market Revenue and Volume Forecast, by Stage
12.4.3. Market Revenue and Volume Forecast, by Distribution Channel
12.4.4. Market Revenue and Volume Forecast, by Disease Cause
12.4.5. GCC
12.4.5.1. Market Revenue and Volume Forecast, by Drug Class
12.4.5.2. Market Revenue and Volume Forecast, by Stage
12.4.5.3. Market Revenue and Volume Forecast, by Distribution Channel
12.4.5.4. Market Revenue and Volume Forecast, by Disease Cause
12.4.6. North Africa
12.4.6.1. Market Revenue and Volume Forecast, by Drug Class
12.4.6.2. Market Revenue and Volume Forecast, by Stage
12.4.6.3. Market Revenue and Volume Forecast, by Distribution Channel
12.4.6.4. Market Revenue and Volume Forecast, by Disease Cause
12.4.7. South Africa
12.4.7.1. Market Revenue and Volume Forecast, by Drug Class
12.4.7.2. Market Revenue and Volume Forecast, by Stage
12.4.7.3. Market Revenue and Volume Forecast, by Distribution Channel
12.4.7.4. Market Revenue and Volume Forecast, by Disease Cause
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Volume Forecast, by Drug Class
12.4.8.2. Market Revenue and Volume Forecast, by Stage
12.4.8.3. Market Revenue and Volume Forecast, by Distribution Channel
12.4.8.4. Market Revenue and Volume Forecast, by Disease Cause
12.5. Latin America
12.5.1. Market Revenue and Volume Forecast, by Drug Class
12.5.2. Market Revenue and Volume Forecast, by Stage
12.5.3. Market Revenue and Volume Forecast, by Distribution Channel
12.5.4. Market Revenue and Volume Forecast, by Disease Cause
12.5.5. Brazil
12.5.5.1. Market Revenue and Volume Forecast, by Drug Class
12.5.5.2. Market Revenue and Volume Forecast, by Stage
12.5.5.3. Market Revenue and Volume Forecast, by Distribution Channel
12.5.5.4. Market Revenue and Volume Forecast, by Disease Cause
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Volume Forecast, by Drug Class
12.5.6.2. Market Revenue and Volume Forecast, by Stage
12.5.6.3. Market Revenue and Volume Forecast, by Distribution Channel
12.5.6.4. Market Revenue and Volume Forecast, by Disease Cause
13.1. Pfizer Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Takeda
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Intercept Pharmaceuticals
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Roche
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Novartis AG
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck & Co. Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. AbbVie Inc.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Gilead Sciences, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Abbott
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample